Another study in Frontiers evaluated the efficacy of triplet combination therapy with BRAF inhibitors, MEK inhibitors, and PD-1/PD-L1 inhibitors in patients with metastatic melanoma. Here, PDCD1 is linked to metastatic melanoma.